An ultrasound-based nonviral delivery platform raised major financing to address gene therapy delivery constraints and repeat dosing.
Key Takeaways
- They’ve become increasingly sophisticated at designing therapies to replace, silence or edit them
- While neither disease sits squarely within the longevity sector
- Modern gene therapies typically rely on modified viruses to carry genetic material into cells